Prestroke Statins, Progression of White Matter Hyperintensities, and Cognitive Decline in Stroke Patients with Confluent White Matter Hyperintensities

Neurotherapeutics

Volumn 11, Issue 3, 2014, Pages 606-611

  Xiong, Yunyun ^a,b   Wong, Adrian ^c   Cavalieri, Margherita ^d   Schmidt, Reinhold ^d   Chu, Winnie W C ^b   Liu, Xinfeng ^a   Wong, Ka Sing ^b   Mok, Vincent ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE EDUCATION UNIVERSITY OF HONG KONG   (Hong Kong)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cognitive decline; Statins; Stroke; White matter hyperintensities

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VITAMIN B GROUP; CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DRUG EFFECT; DRUG USE; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RATING SCALE; STROKE PATIENT; WHITE MATTER; BRAIN CORTEX; CEREBRAL SMALL VESSEL DISEASES; COGNITION DISORDERS; COMPLICATION; PATHOLOGY; VASCULARIZATION;

AGED; CEREBRAL CORTEX; CEREBRAL SMALL VESSEL DISEASES; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; STROKE; VITAMIN B 12; VITAMIN B 6; WHITE MATTER;

EID: 84905581021     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0270-5     Document Type: Article

References (23)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9: 689-701.
2. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341: c3666.
3. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke 2007;38: 2619-2625.
4. Schmidt R, Scheltens P, Erkinjuntti T, et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004;63: 139-144.
5. van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008;39: 2712-2719.
6. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005;112: 1644-1650.
7. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005;65: 1388-1394.
8. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009;40: 1405-1409.
9. ten Dam VH, van den Heuvel DM, van Buchem MA, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005;64: 1807-1809.
10. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9: 855-865.
11. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32: 1318-1322.
12. Mok V, Xiong Y, Wong KK, et al. Predictors for cognitive decline in patients with confluent white matter hyperintensities. Alzheimer Dement 2012;8: S96-S103.
13. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113: e409-e449.
14. Cavalieri M, Schmidt R, Chen C, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012;43: 3266-3270.
15. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361: 2046-2048.
16. Plummer D. DispImage: a display and analysis tool for medical images. Rev Neuroradiol 1992;5: 489-495.
17. Schneider JA. Brain microbleeds and cognitive function. Stroke 2007;38: 1730-1731.
18. Chiu HFK, Kee HC, Chung WS, Kwong PK. Reliability and validity of the Cantonese version of Mini-mental state examination - a preliminary study. J Hong Kong Coll Psychiatry 1994;4(Suppl. 2): 25-28.
19. Chan AS, Choi MK, Salmon DP. The effects of age, education, and gender on the Mattis Dementia Rating Scale performance of elderly Chinese and American individuals. J Gerontol B Psychol Sci Soc Sci 2001;56: P356-P363.
20. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(23 Suppl. 1): III39-43.
21. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003;34: 806-812.
22. Mok VC, Wong A, Lam WW, et al. Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry 2004;75: 560-566.
23. Mok V, Wong KK, Xiong Y, et al. Cortical and frontal atrophy are associated with cognitive impairment in age-related confluent white-matter lesion. J Neurol Neurosurg Psychiatry 2011;82: 52-57.